当前位置: X-MOL 学术Clin. Infect. Dis. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Emergence of Integrase Resistance Mutations During Initial Therapy Containing Dolutegravir
Clinical Infectious Diseases ( IF 8.2 ) Pub Date : 2018-03-21 , DOI: 10.1093/cid/ciy228
Jennifer A Fulcher 1, 2 , Yushen Du 3 , Tian-Hao Zhang 3 , Ren Sun 3 , Raphael J Landovitz 1, 4
Affiliation  

Dolutegravir (DTG) is a preferred drug for initial treatment of human immunodeficiency virus type 1 infection. We present next-generation sequencing analysis of integrase genotypes during a period of virologic failure in a treatment-naive man who initiated tenofovir disoproxil fumarate/emtricitabine plus DTG.

中文翻译:


在含有多替拉韦的初始治疗期间出现整合酶抗性突变



多替拉韦(DTG)是人类免疫缺陷病毒1型感染初始治疗的首选药物。我们对一名首次接受富马酸替诺福韦二吡呋酯/恩曲他滨加 DTG 治疗的初次治疗男性在病毒学失败期间的整合酶基因型进行了新一代测序分析。
更新日期:2018-03-21
down
wechat
bug